Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
about
Emerging targets and novel approaches to Ebola virus prophylaxis and treatmentDelayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesEbola haemorrhagic feverConvalescent plasma: new evidence for an old therapeutic tool?Clinical development of Ebola vaccinesEbola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent UpdatesMouse models for filovirus infectionsStructural basis for differential neutralization of ebolavirusesNeutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against itEbolavirus glycoprotein structure and mechanism of entryStructure of the Ebola virus glycoprotein bound to an antibody from a human survivorAntibodies for biodefenseA neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from diseaseProduction of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal CattleDevelopment of Prototype Filovirus Recombinant Antigen ImmunoassaysAcquired immunity and asymptomatic reservoir impact on frontline and airport ebola outbreak syndromic surveillance and response.H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer modelEnhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.Progress towards the treatment of Ebola haemorrhagic fever.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Neutralizing antibody fails to impact the course of Ebola virus infection in monkeysEstablishment and characterization of a lethal mouse model for the Angola strain of Marburg virusIdentification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virusPost-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Ebola virus pathogenesis: implications for vaccines and therapies.Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.An update on the use of antibodies against the filoviruses.Structures of protective antibodies reveal sites of vulnerability on Ebola virus.Monoclonal antibody specific to HA2 glycopeptide protects mice from H3N2 influenza virus infectionEvasion of the interferon-mediated antiviral response by filoviruses.Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreakVesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycleEbola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infectionPostexposure antibody prophylaxis protects nonhuman primates from filovirus disease.Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
P2860
Q24597625-9BCE3DB1-80C9-43EB-8907-3BCB23C62975Q24612811-285E1125-A696-47CA-80B7-FF22555725A3Q24629338-B7B2BC0F-69A6-4F83-9DDB-CE9F4079F1CEQ26775412-569D0493-E2A4-44ED-8F0A-213495CA8176Q26775792-35932694-E518-47D8-B077-8F1516B32FADQ26798860-335B515E-0C0C-477F-B313-6166D6575531Q27011569-B596AF6B-B214-46D8-93F4-4176044AFAC9Q27014910-A844BBC2-0EC3-4934-A3C3-FB5AD45F184AQ27489891-321FC0C1-EB4C-4204-9B1C-2A18AD147E2AQ27490991-D4CC3C03-FD56-4B43-A075-45945588B4DEQ27651112-F77FBDF2-900F-4A77-9784-58D61FE920D9Q28394941-F634786E-AA3C-4530-8FC2-B109B8F0CA66Q28533408-14000F26-B851-4779-AA18-939D366E1382Q28603849-2A64E6F7-5EE7-426E-97F7-EB87E2940077Q28607807-90BB2084-BA95-41C7-932E-E93072265EC0Q28649707-FB5822EB-34F0-4D6F-A11D-5EC8304D6583Q28741304-DC1CC4B4-908A-4E00-9316-67BCDFC2B66EQ30224854-82930115-B4F5-41A4-B5CB-7C19BEA843C8Q30230272-37F7C0E1-977A-4002-A6B6-C01D6923DD5EQ30252022-F32BB9E2-30FC-45D3-8536-4B29DC308A90Q33269796-58DA7D38-E8D0-41F3-BF78-B5E1123AE179Q33417197-DA3E409F-B0E3-454A-9D64-811B75190D51Q33733844-1C627E5C-24AF-472E-8C9D-C30FCA7C5FF8Q33826350-2C824E28-8586-4254-B0F3-688BB76B280AQ33967985-E11E17D4-FE50-44B6-A8B3-441B7FADF8FCQ34220503-DEF1C737-FE53-4CCF-B8D6-37EA96786C9DQ34257290-926D3067-0889-4DD7-A79E-6D476F4F9F35Q34463780-D08EA897-9683-4C04-A4F6-A6A2F766A3E9Q34657170-060DEF5F-9D17-4169-B580-A150D2C990D2Q34661120-C8E6D89F-81F8-4ED6-9252-617CBC40B0F6Q35190882-B34559E9-12B1-489B-9A1C-51869752302FQ35260239-E4FB2058-99C9-4210-AE79-DC31C8B9334CQ35299756-42785884-7FE3-480B-B880-4FDE1FFC9CCEQ35598919-490CFA61-11CA-443E-9A6E-D62685A97DF2Q35693152-48DE4134-2AA8-4779-B555-B3E85190BDF2Q35793699-774D411C-E364-47BF-BAD1-9CF54872B237Q35802900-E792DD77-257D-4852-9F11-8E516150B1D5Q35842390-5063A22C-A8E1-44D2-8F8F-E97111820869Q35882397-30AB8FD3-1A14-478D-A341-214B877A69B3Q35955731-F13885C4-BEBE-4D18-82D7-48E12061C50F
P2860
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pre- and postexposure prophyla ...... a neutralizing human antibody.
@en
Pre- and postexposure prophyla ...... a neutralizing human antibody.
@nl
type
label
Pre- and postexposure prophyla ...... a neutralizing human antibody.
@en
Pre- and postexposure prophyla ...... a neutralizing human antibody.
@nl
prefLabel
Pre- and postexposure prophyla ...... a neutralizing human antibody.
@en
Pre- and postexposure prophyla ...... a neutralizing human antibody.
@nl
P2093
P2860
P1433
P1476
Pre- and postexposure prophyla ...... a neutralizing human antibody.
@en
P2093
Dennis R Burton
Tom W Geisbert
Toshiaki Maruyama
P2860
P304
P356
10.1128/JVI.76.12.6408-6412.2002
P407
P577
2002-06-01T00:00:00Z